- Inna Khartchenko, MS, MBA
Director, Technology Transfer
215-214-3989
Inna.Khartchenko@fccc.edu - Natalia Shalginskikh, PhD
Licensing Associate, Technology Transfer
267-963-7121
Natalia.Shalginskikh@fccc.edu - Tatiana Venkova, PhD
Licensing Associate, Technology Transfer
215-214-3909; 215-983-0257
Tatiana.Venkova@fccc.edu
Cancer Therapeutics and Discovery Targets
Technology Transfer Contacts
(technologies available for licensing)
Note: Links to Patents may require a browser newer than Internet Explorer 9, such as Chrome, Safari, Firefox, Edge, or Internet Explorer 11| TECH ID | TITLE | LEAD INVENTOR | CONTACT |
|---|---|---|---|
|
02-15 |
ATR kinase: a novel cellular target for anti- retroviral drug discovery and therapy |
Anna Marie Skalka |
|
|
03-13 |
Targeted therapy for ovarian cancer: Anti-Mullerian Inhibiting Substance Type II Receptor (MISIIR) Immunoconjugates to Detect and Treat Cancer |
Gregory Adams |
|
|
06-16 |
Treatment of diseases associated with aberrant ciliary function |
Erica Golemis |
|
|
07-05 |
Compositions and Methods for Altering Pancreas and Liver Functions |
Kenneth Zaret |
|
|
07-29 |
Secreted/cell bound poxvirus proteins and methods of use thereof as vaccines and antiviral agents |
Luis Sigal |
|
|
07-40 |
EFGR/NEDD9/TGF-β Interactome and Methods for the Identification of Agents for the Treatment of Hyperproliferative Disorders |
Igor Astsaturov |
|
|
96-21 |
MED1 (MBD4), A Novel Gene Associated with Cancer Drug Resistance |
Alfonso Bellacosa |
|
|
99-01 |
hCG Therapy for the Treatment of Breast Cancer |
Irma Russo |
|
|
104-JT |
Methods to Treat Hepatitis B and other Liver Disorders |
John Taylor |
|
|
108-YM |
Synergistic Cytotoxic Effects of 5-Fluorouracil Derivatives and 5-Hydroxymethyluracil Derivatives |
Yoshihiro Matsumoto |
|
|
114-EH |
Method for the Treatment of Lymphangioleiomyomatosis (LAM) |
Elizabeth Henske |
|
|
115-IR |
Use of Synthetic Peptides for the Prevention and Treatment of Breast Cancer |
Irma Russo |
|
|
151-EG |
Combination Therapy for the Treatment of Cancer: Aurora A Kinase Inhibitors and Dasatinib |
Erica Golemis |
|
|
196-MM |
Modulators of Hsp70/ Dnak Function |
Maureen Murphy |
|
|
222-HB |
A Highly Specific Antibody Targeting Tumor Endothelial Marker 7R |
Hossein Borghaei |
|
|
243-MC |
Targeting of Cytochrome CYP1B1 in the Treatment of Head and Neck and Lung Cancers |
Margie Clapper |
|
|
250-MA |
New Drug Target Site of HIV Integrase for AIDS Therapy |
Mark Andrake |
|
|
264-JP |
Inhibition of Activated CDC42-Associated Kinase 1 |
Jeffrey Peterson |
|
|
276-GA |
Rationally-designed Anti-Mullerian Inhibiting Substance Type II Receptor Antibodies |
Gregory Adams |
|
|
280-TY |
Combination Inhibition of the Vitamin D Receptor and DNA Replication in the Treatment of Cancer |
Timothy Yen |
|
|
311-AB |
Combination of DNA Repair Inhibition With Bendamustine or Gemcitabine in the Treatment of Cancer |
Alfonso Bellacosa |
|
|
314-VK |
New Anticancer Zinc Chetatin Agents for Therapy of Advanced Prostate Cancer |
Vladimir Kolenko |
|
|
326-NB |
Sensitization of Cancer Cells to DNA Damage by Inhibiting Kinases Essential for DNA Damage Checkpoint Control |
Timothy Yen |
|
|
337-ZY |
Novel Treatment of Medulloblastoma by Inhibition of Leukotriene Synthesis and Activity |
Zeng-Jie Yang |
|
|
346-AB |
Novel Methods for Inhibiting Growth and Proliferation of Melanoma Cells |
Alfonso Bellacosa |
|
|
349-IA |
C-MYC as a Novel Biomarker of Cancer Therapeutic Efficacy |
Igor Astsaturov |
|
|
370-AT |
Novel Class of PARP-1 Blockers for the Treatment of Prostate and Renal Cancers |
Alexei Tulin |
|
|
381-TY |
Combined Inhibition of the Vitamin D Receptor and Poly (ADP) Ribose Polymerase-1 (PARP-1) in Cancer Therapy |
Timothy Yen |
|
|
394-EG |
Systems and Methods for Treating Patients Having a Genetic Predisposition to Develop Prostate Cancer |
Erica Golemis |
|
|
404-WE |
Prodigiosin Analogs as Cancer Therapeutics |
Wafik El-Deiry |
|
|
407-SB |
Viral-Based Cancer Gene Therapy and Treatment of Influenza Infection Through Induction of Cell Death |
Siddharth Balachandran |
|
|
424-WE |
MicroRNA as Targeting CDK4/6-Cell Cycle Pathways Treatment for Cancer |
Wafik El-Deiry |
|
|
425-MA |
Small Molecule Allosteric Inhibitors of HIV Integrase |
Mark Andrake |
|
|
426-SA |
Methods For Diagnosis And Treatment Of Patients Having Solid Tumors |
Sanjeevani Arora |
|
|
427-ZY |
Cholesterol Synthesis Inhibitors Synergize with Smoothened Antagonist for Treatment of Hedgehog Pathway Malignancies |
Zeng-Jie Yang |
|
|
429-RD |
Chimera of Bone Morphogenic Protein 2 and the Mullerian Inhibiting Substance Type II Receptor Binding Region of Mullerian Inhibiting Substance |
Roland Dunbrack |
|
|
430-WE |
Compounds For Repressing Cancer Cell Growth |
Wafik El-Deiry |
|
|
431-WE |
High EGFR Somatic Mutation Frequency Targeting the TK Domain in Colorectal Cancer Patients with Microsatellite Instability (MSI) |
Wafik El-Deiry |
|
|
432-WE |
Dual Inhibition of CDK1 and HSP90 Destabilize HIF1a and Synergistically Induces Cancer Cell Death |
Wafik El-Deiry |
|
|
438-JD |
Generating a Kinome Profile for Cancer Therapy Patent Pending; Summary |
James Duncan |
|
|
439-EC |
Pancreatic Cancer Associated Desmoplastic Immune Checkpoint Inhibitor |
Edna Cukierman |
|
|
441-JR |
Development of a Panel of Markers Predicting Response of Breast Cancer Prevention |
Jose Russo |
|
|
447-WE |
TRAIL Upregulating miRNA with Apoptotic Activity |
Wafik El-Deiry |
|
|
461-PA |
Urinary DNA Detection for Monitoring of Urothelial Cancer Patent Pending; Summary |
Philip Abbosh |
|
|
462-PM |
Combination of Sunitinib with Farnesyl-Transferase Inhibitors as a Next Generation Therapeutic Approach Patent Pending; Summary |
Petr Makhov |
|
|
482-SB (A) |
Pyrido[2,3-D]Pyrimidin-7-Ones and Related Compounds as Inhibitors of RIPK3 to Treat Inflammatory and Degenerative Conditions Patent Pending |
Siddharth Balachandran |
|
|
482-SB (B) |
Protein Kinase Inhibitors and Uses Thereof for the Treatment of Diseases and Conditions Patent Pending |
Siddharth Balachandran |
|
|
484-EC |
Reagent/Drug(s) to Prevent NetricGI/NGLI Engagement Patent Pending |
Edna Cukierman |
|
|
485-JK |
Using Chemical Biology to Enable Precision Immuno-Oncology Patent Pending; Summary |
John Karanicolas |
|
|
494-AP |
Novel Druggable Targets on the Interface of Oncogenic and Metabolic Pathways Patent Pending; Summary |
Andrzej Ptasznik |
|
|
498-PA |
Azolium Salts for Treatment of Non-Muscle Invasive Bladder Cancer Patent Pending |
Philip Abbosh |
|
|
499-JD |
Combination Therapy for Treatment of Cancer (PROTACs and mTORC inhibitors) Patent Pending |
James Duncan |